GlassScriptPhysician profile
Todd B Linden
NPI 1467488460
$7,820.97
in general payments reported to CMS, 2019-2025
40 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $440 · 2021: $1,332 · 2022: $1,470 · 2023: $1,513 · 2024: $1,379 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,695.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,140.59 | 2019-2025 | |
| Qol Medical, LLC | $898.66 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $728.60 | 2019-2024 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $611.15 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $500.34 | 2019-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $460.22 | 2021-2024 | Dificid |
| Pfizer INC. | $448.25 | 2019-2025 | |
| Lilly USA, LLC | $292.05 | 2019-2025 | Omvoh, Mounjaro, Zepbound |
| Celgene Corporation | $258.15 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $124.30 | 2024 | Voquezna |
| Amgen INC. | $122.62 | 2019-2022 | |
| Almatica Pharma LLC | $118.92 | 2024-2025 | Loreev Xr |
| Ferring Pharmaceuticals INC. | $91.23 | 2022-2023 | Clenpiq |
| Amarin Pharma, INC. | $73.26 | 2019-2020 | |
| Ucb, INC. | $66.61 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Linden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.